Source comparison
CJC-1295 Alternative to HGH Therapy: Clinical Comparison
The table below distills the functional, physiological, and practical differences between CJC-1295 and exogenous recombinant HGH across the factors that matter most in clinical decision-making. Mechanism of Action Stimulates endogenous GH release via GHRH rece
This comparison does not assign a generated winner or score.
- The table below distills the functional, physiological, and practical differences between CJC-1295 and exogenous recombinant HGH across the factors that matter most in clinical decision-making.
- Mechanism of Action
- Stimulates endogenous GH release via GHRH receptor agonism at anterior pituitary
- Delivers pre-formed synthetic GH directly into circulation, bypassing natural secretion
- CJC-1295 preserves feedback regulation; HGH overrides it
- Effect on Endogenous GH Production
- Amplifies natural pulsatile secretion; does not suppress endogenous output
- Suppresses endogenous GH via negative feedback; chronic use can cause pituitary atrophy
- CJC-1295 maintains long-term pituitary function; HGH risks permanent suppression
- Dosing Frequency
- 1–2 subcutaneous injections per week (extended half-life of 6–8 days)
- Daily or twice-daily subcutaneous injections (half-life ~2–4 hours)
- CJC-1295 offers superior adherence and convenience
- Peak GH Elevation Above Baseline
- 200–300% increase in mean serum GH; preserves circadian rhythm
- 400–800% increase; constant supra-physiological levels with no circadian variation
- HGH produces higher absolute GH but eliminates natural pulsatility
- Lean Mass Gains (12–24 weeks)
- 1.2–2.8 kg increase in studies of adults with partial GH deficiency
- 4–6 kg increase in high-dose protocols; varies with baseline IGF-1
- HGH delivers greater magnitude; CJC-1295 offers more sustainable, moderate gains
- Risk of Insulin Resistance
- Low. Physiological GH pulses allow insulin sensitivity to normalize between peaks
- Moderate to high. Chronic elevated GH impairs insulin signaling and glucose uptake
- CJC-1295 safer for individuals with pre-diabetes or metabolic syndrome
- Cost (Monthly)
- $80–$150 for research-grade peptide from verified suppliers
- $500–$1,500 depending on dosage and pharmaceutical brand
- CJC-1295 is 70–85% less expensive while delivering clinically meaningful outcomes